Publicacións nas que colabora con Josép María Ribera Santasusana (10)

2010

  1. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era

    European Journal of Haematology, Vol. 85, Núm. 4, pp. 321-328

  2. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic acid and anthracycline-based chemotherapy

    Journal of Clinical Oncology, Vol. 28, Núm. 24, pp. 3872-3879

2008

  1. Practice of central nervous system prophylaxis and treatment in acute leukemias in Spain. Prospective registry study

    Medicina Clinica, Vol. 131, Núm. 11, pp. 401-405

  2. Prospective study on the practice of central nervous system prophylaxis and treatment in non-Hodgkin's lymphoma in Spain

    Medicina Clinica, Vol. 131, Núm. 12, pp. 441-446

2007

  1. Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 trial

    Journal of Clinical Oncology, Vol. 25, Núm. 1, pp. 16-24

  2. Results of compassionate therapy with intrathecal depot liposomal cytarabine in acute myeloid leukemia meningeosis

    International Journal of Hematology, Vol. 86, Núm. 1, pp. 33-36

  3. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia

    European Journal of Haematology, Vol. 78, Núm. 2, pp. 102-110

2006

  1. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: Frequency and prognosis in 467 patients without cranial irradiation for prophylaxis

    Cancer, Vol. 106, Núm. 12, pp. 2540-2546

2001

  1. Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RARα isoforms: A study of the PETHEMA group

    British Journal of Haematology, Vol. 114, Núm. 1, pp. 99-103

1999

  1. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia

    Blood, Vol. 94, Núm. 9, pp. 3015-3021